Skip Navigation Links
Review of Senseonics (SENS) - 25 Nov 2021
25 Nov 2021 (173 views)  

I hold 20,000 shares of SENS at average cost of $3.58 USD, totallying $71,600. The current price is $3.27 giving me a loss of $6,100.

The current price shows a discount of 42% from the peak price of $5.56 during the past year. 

The main event that will move the price of SENS is the likely approval of their 180 day Eversense CGM (continuous glucose monitor). The test results are positive. The approval by the Food and Drug Administration was expected to be given last August, but has been delayed due to the covid pandemic. 

The approval is expected "in coming months".

Here is a report on the financial results for the third quarter of 2021.

My target is to sell the stock at $5. But I may sell it at a lower price of $4.50.

Note - I am sharing my investing experience. This is not investment advice. 

Tan Kin Lian

 


Review of Senseonics (SENS) - 25 Nov 2021
[Back] [Print]


I hold 20,000 shares of SENS at average cost of $3.58 USD, totallying $71,600. The current price is $3.27 giving me a loss of $6,100.

The current price shows a discount of 42% from the peak price of $5.56 during the past year. 

The main event that will move the price of SENS is the likely approval of their 180 day Eversense CGM (continuous glucose monitor). The test results are positive. The approval by the Food and Drug Administration was expected to be given last August, but has been delayed due to the covid pandemic. 

The approval is expected "in coming months".

Here is a report on the financial results for the third quarter of 2021.

My target is to sell the stock at $5. But I may sell it at a lower price of $4.50.

Note - I am sharing my investing experience. This is not investment advice. 

Tan Kin Lian